ÍøºìºÚÁÏ

Skip to main content

Paul L Crispen, MD : Research

Cancer Specialist (Oncologist), Urologist

Photo of Paul L Crispen

Research at a glance

Top areas of exploration

  • Kidney Neoplasms , 39 publications
  • Carcinoma, Renal Cell , 28 publications
  • Nephrectomy , 20 publications
  • Prostatic Neoplasms , 16 publications

Research activity

95 publications

4,527 citations

Why is this important?

Active clinical trials

Intravesical Gemcitabine and Docetaxel for Low Grade Intermediate Risk Bladder Cancer

Bladder cancer is the 8th most common cancer in the ÍøºìºÚÁÏ Cancer Center catchment area and the 7th most common cancer presenting to UFÍøºìºÚÁÏ. Most newly diagnosed cases are stage I bladder cancer, which is defined by having no deep muscle…

Investigator
Paul L Crispen
Status
Accepting Candidates
Ages
18 Years - N/A
Sexes
All

My publications

95 publications

2021

Intravesical nadofaragene firadenovec gene therapy for BCG-unresponsive non-muscle-invasive bladder cancer: a single-arm, open-label, repeat-dose clinical trial.

The Lancet. Oncology

•

2021

Patient and Procedural Determinants of Postoperative Pain Trajectories.

Anesthesiology

•

2021

Predicting long-term postsurgical pain by examining the evolution of acute pain.

European journal of pain (London, England)

•

2021

Validation of aorta-lesion-attenuation difference on preoperative contrast-enhanced computed tomography scan to differentiate between malignant and benign oncocytic renal tumors.

Abdominal radiology (New York)

•

2020

Mechanisms of immune evasion in bladder cancer.

Cancer immunology, immunotherapy : CII

•